ethyl 6-chloro-7-((2,5-dimethylpyrrolidin-1-yl)methyl)-2-(trifluoromethyl)-2H-chromene-3-carboxylate | 1260238-31-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: ethyl 6-chloro-7-((2,5-dimethylpyrrolidin-1-yl)methyl)-2-(trifluoromethyl)-2H-chromene-3-carboxylate
• CAS: 1260238-31-0
• 化学式: C₂₀H₂₃ClF₃NO₃
• 分子量: 417.856
• InChiKey: XFZJQKFAMPNRCN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.98
• 重原子数：
  28.0
• 可旋转键数：
  4.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  38.77
• 氢给体数：
  0.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  ethyl 6-chloro-7-((2,5-dimethylpyrrolidin-1-yl)methyl)-2-(trifluoromethyl)-2H-chromene-3-carboxylate 在 水 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 6-chloro-7-((2,5-dimethylpyrrolidin-1-yl)methyl)-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid
  参考文献：
  名称：

  The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: The second clinical candidate having a shorter and favorable human half-life

  摘要：

  In this Letter, we provide the structure-activity relationships, optimization of design, testing criteria, and human half-life data for a series of selective COX-2 inhibitors. During the course of our structure-based drug design efforts, we discovered two distinct binding modes within the COX-2 active site for differently substituted members of this class. The challenge of a undesirably long human half-life for the first clinical candidate 1 t(1/2) = 360 h was addressed by multiple strategies, leading to the discovery of 29b-(S) (SC-75416) with t(1/2) = 34 h. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.07.054
• 作为产物：
  描述：

  2,5-二甲基吡咯烷 、 ethyl 6-chloro-7-(bromomethyl)-2-(trifluoromethyl)-2H-chromene-3-carboxylate 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 ethyl 6-chloro-7-((2,5-dimethylpyrrolidin-1-yl)methyl)-2-(trifluoromethyl)-2H-chromene-3-carboxylate
  参考文献：
  名称：

  The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part 2: The second clinical candidate having a shorter and favorable human half-life

  摘要：

  In this Letter, we provide the structure-activity relationships, optimization of design, testing criteria, and human half-life data for a series of selective COX-2 inhibitors. During the course of our structure-based drug design efforts, we discovered two distinct binding modes within the COX-2 active site for differently substituted members of this class. The challenge of a undesirably long human half-life for the first clinical candidate 1 t(1/2) = 360 h was addressed by multiple strategies, leading to the discovery of 29b-(S) (SC-75416) with t(1/2) = 34 h. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.07.054